Hanlizhuang® (Serplulimab, European brand name: Hetronifly®), a groundbreaking anti-PD-1 monoclonal antibody, has been approved in the UK and India for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). This makes it the world's first such antibody to be used in this capacity. Currently marketed in nearly 40 countries and regions, including China, Europe, India, and Southeast Asia, Hanlizhuang® has already benefited over 110,000 patients. The latest approvals in the UK and India are supported by long-term follow-up data from the ASTRUM-005 study, revealing that Serplulimab, when combined with chemotherapy, significantly enhances patients' 4-year overall survival rate. Independently developed by Hanli Biologics, this drug is distributed in Europe and India by Intas and its subsidiary Accord Healthcare. Hanli Biologics is actively pursuing head-to-head bridging studies of this drug in the United States and Japan, aiming to achieve global registration and extend high-quality innovative immunotherapy to even more patients worldwide.